Ikarian Capital, LLC Tricida, Inc. Transaction History

Ikarian Capital, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$4.19 - $9.56 $2.81 Million - $6.41 Million	-670,771 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$3.56 - $4.64 $372,101 - $484,986	-104,523 Reduced 13.48%	670,771 $3.11 Million
Q1 2021 May 17, 2021	SELL	$4.52 - $7.8 $377,935 - $652,189	-83,614 Reduced 9.73%	775,294 $4.1 Million
Q4 2020 Feb 12, 2021	BUY	$4.37 - $9.46 $3.65 Million - $7.91 Million	835,715 Added 3603.31%	858,908 $6.06 Million
Q3 2020 Nov 16, 2020	SELL	$8.56 - $26.93 $1.32 Million - $4.14 Million	-153,809 Reduced 86.9%	23,193 $210,000
Q2 2020 Aug 14, 2020	SELL	$21.21 - $31.55 $59,345 - $88,276	-2,798 Reduced 1.56%	177,002 $4.86 Million
Q1 2020 May 15, 2020	BUY	$18.43 - $38.04 $3.31 Million - $6.84 Million	179,800 New	179,800 $3.96 Million

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.